Guardant Health Inc. (NASDAQ: GH)’s stock price has increased by 5.53 compared to its previous closing price of 26.78. Despite this, the company has seen a gain of 4.90% in its stock price over the last five trading days.
Is It Worth Investing in Guardant Health Inc. (NASDAQ: GH) Right Now?
The 36-month beta value for GH is also noteworthy at 0.87. There are mixed opinions on the stock, with 16 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
The average price estimated by analysts for GH is $55.94, which is $27.68 above than the current price. The public float for GH is 97.63M, and at present, short sellers hold a 7.17% of that float. The average trading volume of GH on March 17, 2023 was 2.22M shares.
GH’s Market Performance
GH’s stock has seen a 4.90% increase for the week, with a 1.22% rise in the past month and a -36.89% fall in the past quarter. The volatility ratio for the week is 6.97%, and the volatility levels for the past 30 days are at 6.44% for Guardant Health Inc. The simple moving average for the last 20 days is -0.85% for GH stock, with a simple moving average of -33.99% for the last 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Citigroup repeating the rating for GH by listing it as a “Neutral.” The predicted price for GH in the upcoming period, according to Citigroup is $33 based on the research report published on March 09th of the current year 2023.
Scotiabank, on the other hand, stated in their research note that they expect to see GH reach a price target of $36. The rating they have provided for GH stocks is “Sector Outperform” according to the report published on January 05th, 2023.
Piper Sandler gave a rating of “Neutral” to GH, setting the target price at $50 in the report published on November 01st of the previous year.
GH Trading at -3.95% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.64% of loss for the given period.
Volatility was left at 6.44%, however, over the last 30 days, the volatility rate increased by 6.97%, as shares sank -2.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.67% upper at present.
During the last 5 trading sessions, GH rose by +4.90%, which changed the moving average for the period of 200-days by -34.28% in comparison to the 20-day moving average, which settled at $28.47. In addition, Guardant Health Inc. saw 3.90% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at GH starting from Eltoukhy Helmy, who purchase 8,600 shares at the price of $26.15 back on Mar 15. After this action, Eltoukhy Helmy now owns 2,049,238 shares of Guardant Health Inc., valued at $224,928 using the latest closing price.
Eltoukhy Helmy, the Co-Chief Executive Officer of Guardant Health Inc., purchase 84,452 shares at $26.33 during a trade that took place back on Mar 14, which means that Eltoukhy Helmy is holding 2,040,638 shares at $2,223,908 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -118.98 for the present operating margin
- +64.88 for the gross margin
The net margin for Guardant Health Inc. stands at -145.61. Equity return is now at value -242.70, with -35.90 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.17.
In summary, Guardant Health Inc. (GH) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.